

1 **Prevalence of multimorbidity combinations and their association with**
2 **medical costs and poor health: a population-based study of U.S.**
3 **adults**

4

5 **Nicholas K. Schiltz, PhD¹**

6 ¹Frances Payne Bolton School of Nursing, Case Western Reserve University, Cleveland, Ohio,
7 USA

8 ²Department of Population & Quantitative Health Sciences, Case Western Reserve University
9 School of Medicine, Cleveland, Ohio, USA

10 ³Center for Community Health Integration, Case Western Reserve University School of
11 Medicine, Cleveland, Ohio, USA

12

13 *** Correspondence:**

14 Nicholas K. Schiltz, PhD

15 nks8@case.edu

16

17 **Keywords: Multimorbidity, Comorbidity, Multiple Chronic Conditions, Chronic Disease,**
18 **Practice Guidelines as Topic, Health status, Healthcare economics, Epidemiology**

19

20 **ABSTRACT**

21 **BACKGROUND:** Multimorbidity is common, but the prevalence and burden of the specific
22 combinations of coexisting disease has not been systematically examined in the general U.S.
23 adult population.

24 **OBJECTIVE:** To identify and estimate the burden of highly prevalent combinations of chronic
25 conditions that are treated among one million or more adults in the United States.

26 **METHODS:** Cross-sectional analysis of U.S. households in the Medical Expenditure Panel
27 Survey (MEPS), 2016–2019, a large nationally-representative sample of the community-
28 dwelling population. Association rule mining was used to identify the most common
29 combinations of 20 chronic conditions that have high relevance, impact, and prevalence in
30 primary care. The main measures and outcomes were annual treated prevalence, total medical
31 expenditures, and perceived poor health. Logistic regression was used to calculate adjusted
32 odds ratios and 95% confidence intervals.

33 **RESULTS:** Frequent pattern mining yielded 223 unique combinations of chronic disease,
34 including 74 two-way (dyad), 115 three-way (triad), and 34 four-way combinations that are
35 treated in one million or more U.S. adults. Hypertension-hyperlipidemia was the most common
36 two-way combination occurring in 30.8 million adults. The combination of diabetes-arthritis-
37 cardiovascular disease was associated with the highest median annual medical expenditures
38 (\$23,850, [Interquartile range: \$11,593 – \$44,616]), and the combination of diabetes-arthritis-
39 asthma/COPD} had the highest age-race-sex adjusted odds ratio of poor self-rated health
40 (adjusted odd ratio: 6.9, [95%CI: 5.4 – 8.8]).

41 **CONCLUSION:** This study demonstrates that many multimorbidity combinations are highly
42 prevalent among U.S. adults, yet most research and practice-guidelines remain single disease
43 focused. Highly prevalent and burdensome multimorbidity combinations could be prioritized for
44 evidence-based research on optimal prevention and treatment strategies.

45

46 INTRODUCTION

47 An estimated 42% percent of American adults 18 and older suffer from multiple chronic
48 conditions (i.e. multimorbidity).¹ Persons with multimorbidity have higher mortality rates, lower
49 health-related quality life, increased healthcare use, and are at higher risk for many poor health
50 outcome events including adverse drug events.²⁻⁶

51 Despite the high frequency of multimorbidity in the population, most clinical practice guidelines,
52 and the evidence they are based upon are single disease focused. Adhering to multiple,
53 sometimes conflicting, guidelines for multiple individual diseases is burdensome⁷ and conveys
54 considerable risk to the patient in terms of drug-drug or drug-disease interactions.^{8,9} The overall
55 optimal treatment plan for a given patient with multimorbidity is unlikely to be the linear
56 combination of the best treatment for each individual condition.^{9,10} There is a clear need to
57 develop guidelines, care management plans, and patient education programs that meet the
58 needs of patients with multimorbidity. Understanding which conditions most commonly coexist
59 together and their impact on outcomes is a critical first step to establish research priorities for
60 building the evidence-base necessary to achieve this.

61 Understanding the rate that disease coexist or cluster together at higher-than-expected rates,
62 may also provide clues about the etiology between two or more conditions. For example,
63 inflammation has been shown to be a mechanism for numerous conditions including cancer,
64 cardiovascular disease, chronic kidney disease, and diabetes.¹¹ Damage caused by vascular
65 diseases may be a cause of Alzheimer's Disease and other dementias.¹² Understanding these
66 shared risk factors and pathways could lead to the development of medications or behavioral
67 interventions that target more than one condition simultaneously, hence reducing polypharmacy
68 and treatment burden in this population.

69 While numerous data exist on the prevalence of single chronic conditions^{1,13}, much less is
70 known about the prevalence of *specific combinations* of multimorbidity. Most prevalence studies
71 of multimorbidity are based on counts of conditions.^{14,15} However, measuring the impact of
72 multimorbidity based on counts of conditions or weighted scores may miss important
73 heterogeneity, because the specific combinations of chronic disease matter in terms of health
74 outcomes¹⁶ including mortality and poor health,⁵ activity of daily living and instrumental activity
75 of daily living limitations,^{17,18} cost and utilization,⁶ and quality of care.¹⁹

76 Studies that have examined the prevalence of specific combinations of multimorbidity in the US
77 have been mostly limited to dyad and triad combinations,²⁰⁻²³ a small number of conditions,^{17,24}
78 conducted in a specific sub-populations²¹ or geographic areas,²⁵ or limited to older adults.^{24,26}
79 The prevalence of specific multimorbidity combinations of the general community-dwelling adult
80 population has not been established comprehensively in the United States.

81 The goal of this study was to fill this knowledge gap and identify and rank the most frequent
82 multiway (two-way, three-way, four-way, etc...) combinations of multimorbidity treated among
83 adults in the United States. An innovative machine learning algorithm –association rule mining –
84 was used to identify all combinations of multimorbidity occurring in one million or more U.S.

85 adults. The association with average and median per capita direct medical expenditures and
86 perceived fair or poor health status was also examined, to identify combinations associated with
87 the most burden.

88 **METHODS**

89 **Design, Setting, and Participants**

90 This study was a cross-sectional analysis of the 2016 – 2019 Medical Expenditure Panel Survey
91 Household Component (MEPS). The MEPS is a large-scale panel survey of a nationally
92 representative sample of households in the United States and is administered by the Agency for
93 Healthcare Research and Quality (AHRQ).²⁷ The MEPS collects data at the person-level on
94 numerous topics including medical expenditures, utilization, medical conditions, health status,
95 and demographics. Interviews are conducted in-person using computer-assisted personal
96 interview (CAPI) technology. The MEPS is designed in a way that it can be used for both
97 longitudinal analysis over a two-year period, and cross-sectional analysis to obtain annual
98 estimates in a single year,²⁸ or pooled across multiple years.²⁹ This study uses cross-sectional
99 methods and weights as the main goal was to produce national estimates of prevalence. The
100 2016 – 2019 data was chosen as these are the most recent currently available data and earlier
101 years used ICD-9-CM coding for medical conditions. Multiple years of data were pooled
102 together to provide a larger sample size as some combinations will occur in less than 1% of the
103 total study population.²⁹ This study included all adults age 18 and older with non-zero weights.
104 Subjects with missing data on self-reported health or expenditures were excluded (n≤10). The
105 final unweighted sample was 89,947 adults (Supplementary Figure 1).

106 **Ethics Statement**

107 The MEPS data used in this study is publicly available and de-identified. The Case Western
108 Reserve University Institutional Review Board reviewed the protocol for this study and deemed
109 it to be exempt under U.S. federal law.

110 **Measures**

111 Health conditions were self-reported through open-ended questions about conditions reported to
112 be treated with prescription medications or associated with health care utilization.³⁰ The
113 respondents verbatim text responses were coded according to the International Classification of
114 Diseases, Tenth Revision, Clinical Modification (ICD-10-CM). Treatment of these conditions
115 may have been received through inpatient stays, outpatient or office-based visits, emergency
116 department visits, home health care, or prescribed medications. Chronic conditions were then
117 classified into one of 20 chronic conditions used in recent studies of multimorbidity, because of
118 their high relevance, impact, and prevalence among primary care clientele.^{31–33} A list of each
119 chronic condition categories and corresponding ICD-10-CM codes is included in the appendix
120 (Supplementary Table 1).

121 Perceived health was assessed by asking respondents to rate their health as excellent (1), very
122 good (2), good (3), fair (4), or poor (5). The variable was dichotomized into two values: a
123 response of excellent, very good, or good was categorized as good perceived health, while a
124 response of fair or poor was categorized as poor perceived health.

125 Medical expenditures were defined as the sum of direct payments for care provided during the
126 year, including out-of-pocket payments and payments by private insurance, Medicaid, Medicare,
127 and other sources. Expenditure data were collected in the MEPS through both self-report and
128 through data collected from the respondents' physicians, hospitals, and pharmacies, when
129 available. The MEPS provides imputed values when data are missing or payments are made
130 under capitated plans.³⁴ Total expenditures were adjusted for annual inflation and are reported
131 in terms of 2019 dollars using the Personal Consumption Expenditure Health Price Index from
132 the Bureau of Economic Analysis.³⁵ Out-of-pocket expenditures were adjusted for inflation using
133 the Consumer Price indices for medical care (CPI-M).³⁵

134 **Statistical Analysis:**

135 The main analytic techniques in this study were association rule mining and frequent pattern
136 mining.³⁶ In brief, association rule mining can be thought of as a two-step process. In the first
137 step (frequent pattern mining) all combinations of items with a minimum support (i.e. prevalence
138 in the study population) are discovered. In the second step, "association rules" of the form $X = >$
139 Y are created, where X is one or more items (chronic conditions in this study) and Y is a single-
140 item consequent (poor health or medical expenditures in our study) that X is associated with.

141 The method was applied here by treating each subject in the study data as the "transaction,"
142 and each chronic condition as the "items" to find the most frequently coexisting combinations
143 out of the 1,048,576 (2^{20}) possible combinations of 20 conditions. The minimum support
144 (prevalence) threshold was set at 0.20% for the initial pass, and then after applying survey
145 weights, any combinations with a point estimate of less than one million adults (~0.40% of the
146 U.S. adult population) was dropped.

147 The MEPS uses a complex stratified random sampling design. Design-based survey methods
148 (i.e. Taylor series estimation) were used to account for stratification and clustering effects when
149 estimating variances.³⁷ Person-level weights in each year were divided by four (number of total
150 years of data) and applied to get the annualized estimated number and percent of persons with
151 a disease combination and 95% confidence interval.²⁸ Likewise, the median and average annual
152 per capita medical expenditures, per capita out-of-pocket expenses, and percent self-reporting
153 poor health status was calculated for each combination after applying weights.

154 Combinations of conditions and corresponding prevalence estimates represent "at least", rather
155 than "exactly." For example, people with hypertension-hyperlipidemia-diabetes would be a
156 subset of the people with hypertension-diabetes.

157 For each combination, we calculated the observed-to-expected prevalence ratio (also known as
158 lift), which is the observed prevalence of the combination divided by the expected prevalence

159 given all single diseases in the combination are independent of each other. Lift significantly
160 greater (or lower) than 1 indicates the coexistence of diseases is unlikely due to chance alone.

161 To identify specific combinations associated with the highest average cost and perceived poor
162 health burden, we filtered out combinations that were redundant in that they offered little new
163 information on the outcome measure over a more parsimonious (i.e. superset) combination,
164 using a minimum improvement criteria of 10%.^{38,39}

165 Survey-weighted logistic regression was used to estimate the age-race-sex adjusted odds ratio
166 of poor health status for each disease combination, account for clustering and stratification.
167 Adjustment variables were age as a continuous variable with splines, race (Hispanic, non-
168 Hispanic white, non-Hispanic black, non-Hispanic Asian, and other), and sex. Subgroup
169 analysis was performed by sex as a secondary analysis.

170 Data pre-processing was performed using SAS version 9.4 for Windows. The analysis was
171 conducted using R version 4.1.0, RStudio (v. 1.4.1717), and R packages: arules (v. 1.6-8) and
172 survey (v. 4.1-1).^{40,41}

173 RESULTS

174 The total weighted study population was 249.2 million adults age 18 and older, with 82.0 million
175 (32.9%) reporting receiving treatment for two or more conditions (Table 1) in a single year. 51.7
176 million (20.7%) adults have three or more conditions, and 30.6 million (12.3%) have 4 or more
177 conditions. A dose response increase is evident between number of chronic conditions and the
178 percentage reporting poor perceived health and average annual medical expenditures. The
179 prevalence of multimorbidity is highest in those ages 65 and older (73.0% or 38.0 million
180 people), followed by age 40 to 64 (35% or 36.4 million people), and 18-39 (7.9% or 7.5 million).

181 Frequent pattern mining yielded 223 unique combinations of chronic disease, including 74 two-
182 way, 115 three-way, and 34 four-way combinations that affect one million or more of the
183 weighted study population. There are eight combinations that affect 10 million or more adults,
184 32 combinations that affect 5 million or more adults, and 129 that affect 2 million or more adults
185 per year. There were not any five-way or higher combinations that met the minimum prevalence
186 threshold. The full table is included in the supplementary material (Supplementary Table 2).

187 Figure 1 shows the most prevalent combinations along with their associated total medical
188 expenditures (in billions of U.S. Dollars) and percent of the population reporting poor perceived
189 health. An estimated 30.8 million people (12.4%, 95%CI: 12.0 - 12.8%) of the U.S. adult
190 population are treated for hypertension and hyperlipidemia – the most common combination
191 (Table 2). An estimated 11.5 million people (4.6%, 95%CI: 4.4% – 4.9%) have hypertension,
192 hyperlipidemia, and diabetes – the most common 3-way combination, and fifth most common
193 combination overall. Hypertension, hyperlipidemia, musculoskeletal disorder, diabetes and
194 arthritis was the most common 5-way combination (1.1%, 95%CI: 1.0% – 1.2%). Combinations
195 including hypertension and/or hyperlipidemia plus another condition comprise the majority of the

196 most prevalent combinations. An alternate version of the analysis excluding hypertension and
197 hyperlipidemia is included in the supplement (Supplementary Figure 2).

198 All 223 combinations identified as highly prevalent had O/E ratios (and 95% confidence
199 intervals) greater than 1, indicating the coexistence of these two conditions is unlikely due to
200 chance alone. The combination of hypertension, hyperlipidemia, diabetes, and cardiovascular
201 disease had the highest observed-to-expected ratio of 38.6 (36.4 - 40.9). Cardiovascular
202 disease and heart failure had the highest O/E of 7.4 (95% CI: 6.8 – 8.2%) for dyad combinations
203 and hypertension, cardiovascular disease, and diabetes had the highest O/E of 11.4 (10.8 -
204 12.0) for triad conditions.

205 Figure 2 shows specific combinations of multimorbidity that ranked in either the top 20 in terms
206 of average medical expenditures or perceived poor health. A total of 28 combinations met either
207 criteria, and 12 met both. The combination of heart failure and cardiovascular disease had the
208 highest average annual medical expenditures per capita (\$33,451, 95%CI: \$29,034 – \$ 37,868).
209 This was 2.4 times higher than the average for having any two or more chronic conditions
210 (\$13,907). Average expenditures were higher than median expenditures across the board,
211 indicating the right-skewed nature of expenditures. The combination of diabetes, asthma/COPD,
212 and arthritis was most associated with perceived poor health status with an adjusted odds ratio
213 of 6.9 (5.4 – 8.8) (Figure 2). The 62.9% reporting poor health was 2.1 times higher than the
214 average percent reporting poor health among those with any three or more chronic conditions.
215 Supplementary Table 2 provide additional details on the out-of-pocket expenses associated with
216 each combination, and Supplemental Figure 3 shows combinations with the highest average
217 out-of-pocket expenditures.

218 The top ten combinations among male and female adults in the study population is shown in
219 Figure 3. Hypertension and hyperlipidemia was the top combination for both, but after that the
220 results diverge. Hypertension and diabetes was 2nd for males, but 4th for females. Hypertension
221 and chronic musculoskeletal conditions were 2nd for females, but 4th for males. Combinations
222 with urinary problems appeared twice in the top ten ranking for males, but not for females.
223 Combinations with arthritis, thyroid disorders, stomach problems, and asthma/COPD appeared
224 in the top ten for females but not males.

225 **DISCUSSION**

226 This study combined data mining with survey epidemiology to comprehensively identify and
227 estimate the treatment prevalence of the most frequent combinations of multimorbidity in the
228 United States. This analysis showed that certain multimorbidity combinations of disease are not
229 idiosyncratic, but actually quite common in the US, occurring in one million or more adults.

230 This paper adds several new contributions to the literature. First, we provide important public
231 health data on the prevalence and associated outcomes of specific multimorbidity combinations.
232 While it was not surprising to find hypertension and hyperlipidemia as the top combination, a
233 fact that is well-established,⁴² the approximate ranking and estimated prevalence of many other
234 combinations farther down the list was previously unknown. Second, this study provides data on

235 observed-to-expected prevalence ratio for each combination. Disease with high ratios likely
236 share risk factors or have common pathways for disease, which could spur hypotheses for
237 future research. Finally, we identify combinations with the highest burden in terms of total
238 expenditures and perceived poor health. These combinations could be priority targets for future
239 prevention or treatment interventions targeted toward multimorbidity patients.

240 Despite the high prevalence of these disease combinations, most evidence-based practice
241 guidelines are single-disease focused.⁴³ This relegates managing people with multimorbidity,
242 who represent the majority of people presenting for primary care,^{44,45} to the “art”, rather than the
243 science of medicine, and has led to largely untargeted global interventions that show limited or
244 no effect in clinical trials.⁴⁶ While general approaches for complex patients exist including
245 geriatric care teams,⁴⁷ the Age-Friendly Health Systems 4M model of care,⁴⁸ and deprescribing
246 guidelines (e.g. Beers Criteria and STOPP/START),^{49,50} significant evidence gaps remain
247 especially when it comes to specific guidelines for managing patients with specific combinations
248 of conditions. For some conditions, multimorbidity may be the norm. For example, this study
249 showed that 45 million adults are treated for hyperlipidemia, and of those approximately two-
250 thirds are treated for hypertension as well. This means it is more common for a patient to be
251 treated for high cholesterol plus another condition, than just managing cholesterol alone.

252 The highly prevalent combinations identified in this study could be prioritized for future
253 evidence-based research. Some combinations show the possibility that a single medication
254 could target multiple diseases thus reducing the polypharmacy. For example, a low-dose
255 antidepressant for anxiety, can also treat pain from arthritis or diabetic neuropathy. Other
256 common combinations show the potential of physical activity, diet, and tobacco cessation
257 interventions to positively affect multiple conditions and reduce medication burden.

258 This was, to the author’s knowledge, the most comprehensive, population-based study in the
259 U.S. on the prevalence and associated impact of multimorbidity combinations in terms of the
260 number of conditions, the examination of higher-order combinations (e.g. 4-way or deeper), and
261 the broadness of the study population. Ward and Schiller examined common dyad and triad
262 combinations of ten conditions using the National Health Interview Survey.²³ The most common
263 dyad condition was hypertension-arthritis and 26% of adults had multimorbidity. A similar more
264 recent study using 2018 NHIS data estimated that 27.2% of U.S. adults had two or more.⁵¹
265 Weiss et al, used survey weights and examined deeper combinations of chronic disease, but
266 only in five conditions using 1999-2004 National Health and Nutrition Examination Survey
267 (NHANES) data.²⁴

268 Several studies have been conducted in specific subpopulations of the U.S. using ARM or
269 similar methods to examine combinations of multimorbidity. Koroukian et al. used ARM to
270 identify combinations of multimorbidity associated with high expenditures among Medicare
271 enrollees.²⁶ Ho et al. used ARM to identify high-risk comorbidity combinations for patients
272 undergoing emergency general surgery using the Nationwide Inpatient Sample.³⁸ Quinones et
273 al. (2016) and Quinones et al. (2019) examined diabetes comorbidities and racial disparities in
274 multimorbidity, respectively using the Health & Retirement Study.^{17,52} Quinones et al. (2022)
275 examined combinations associated of multimorbidity among patients seeking care at community

276 health centers.⁵³ Steinman et al. examined combinations of multimorbidity impacting older
277 veterans using data from the Veterans Affairs health system.²¹

278 Comparable studies have been conducted internationally outside the U.S., including a study
279 using the Korea Health Panel which found an overall multimorbidity rate of 34.8% in South
280 Korea,⁵⁴ and a study using Beijing medical claims data in China, which found a higher rate of
281 multimorbidity than our study (51.6% in mid-life adults and 81.3% in older adults). This is
282 probably due to including more conditions. Zemekidun et al. applied cluster analysis and ARM
283 to the UK biobank to identify combinations of multimorbidity.⁵⁵ Britt et al. examined prevalence
284 and patterns of multimorbidity in patient-reported surveys in Australia across nine morbidity
285 domains.⁵⁶ The most common combination was arthritis/chronic back pain + vascular disease
286 (15% of population). Nicholson et al. developed a cluster analysis tool to identify common
287 combinations and sequences in Canada using an approach that seems similar to association
288 rule mining.³²

289 **Strengths**

290 The data mining allowed a more comprehensive identification of high frequency multimorbidity
291 combinations than previous efforts.^{23,24} This study uses a national sample, representative of the
292 U.S. population. The MEPS database is also unique among national surveys in that its open-
293 ended condition enumeration approach (rather than a fixed set of questions) allows for a more
294 comprehensive capture of different chronic conditions, compared to other national
295 surveys.^{17,23,24} MEPS covers all payers (even uninsured) and has data on services from all
296 providers, which is an advantage over big data sources like claims data and electronic health
297 records, respectively.

298 Association rule mining allows for the identification of highly prevalent combinations in a quick
299 and computationally efficient manner, while filtering out combinations that have no observations
300 or are sparse. While our study only focused on combinations occurring in over 1 million adults,
301 the method could also be used to identify higher order combinations by setting a lower
302 prevalence thresholds. Association rule mining is still relatively uncommon in clinical and
303 epidemiological studies. The method could be applied to other areas of research, for example
304 identifying high-risk combinations of risk factors associated with mortality,³⁸ social determinant
305 of health indicators associated with disparities,⁵⁷ or prescription drug combinations associated
306 with adverse drug events.⁵⁸ To our knowledge, this is the first study to combine complex survey
307 analysis with association rule mining to yield national estimates of combinations of variables.

308 **Limitations**

309 MEPS provides accurate estimates of treated prevalence for chronic disease, but this is likely
310 lower than the underlying population prevalence for some conditions, especially those that are
311 less salient.³⁰ On the other hand, the focus on treated conditions represent those for which care
312 decisions between multiple conditions may conflict. The MEPS includes community-dwelling
313 subjects only, meaning institutionalized persons such as nursing home and assisted living
314 residents are excluded. Estimates of total expenditures are typically lower than what is

315 estimated from the National Health Expenditure Accounts (NHEA), because the MEPS does not
316 include these institutionalized populations.⁵⁹ ICD-10 codes were classified into 20 primary-care
317 relevant conditions using an established algorithm, but other classification systems may result in
318 different combinations and prevalence estimates.³¹ This algorithm was chosen over others
319 because it was originally designed for use on self-reported conditions, and that it could be
320 applied with the 3-digit ICD-10 codes available in MEPS. Many other algorithms require the use
321 of fully-specified ICD-10 codes and/or were designed for use in administrative data, including
322 Elixhauser comorbidities,⁶⁰ Deyo-Charlson Comorbidity Index,^{61,62} Clinical Classification
323 Software,⁶³ and Phecodes.⁶⁴ Consensus on which conditions to include in measures of
324 multimorbidity has not been established, and is a problem that continues to plague the field.⁶⁵

325 This study used the most recent data (2016-2019) available at the time; therefore, the impact of
326 the COVID-19 pandemic was not captured in these results. As comorbidities were among the
327 greatest risk factors of COVID-related death, excess mortality in people with multimorbidity
328 could have lowered population prevalence rates.⁶⁶⁻⁶⁸ However, there is growing evidence of
329 increases in prevalence of certain post-Covid conditions (i.e. long COVID) including respiratory
330 problems, diabetes, heart conditions, neurological conditions, migraines, and mental health
331 conditions.⁶⁹⁻⁷³ Understanding the scale and impact of post-COVID conditions is an on-going
332 area of investigation in the scientific community.

333 **Conclusion**

334 This cross-sectional analysis of a nationally-representative survey showed that certain
335 multimorbidity combinations of disease are quite common in the US, occurring in one million or
336 more adults. The combinations reported here could be prioritized for evidence-based research
337 and integration into practice guidelines, especially those most associated with poor health and
338 high medical costs.

339

340 **DATA AVAILABILITY STATEMENT**

341 This study uses openly available data from the Medical Expenditure Panel Survey. Available at:
342 https://www.meps.ahrq.gov/mepsweb/data_stats/download_data_files.jsp. Requests to access
343 the processed dataset used in analysis should contact the corresponding author. Project code is
344 posted on the author's GitHub: <https://github.com/nickschiltz/multimorbidity-prevalence>

345

346 **ETHICS STATEMENT**

347 This study uses only publicly available deidentified datasets. The Case Western Reserve
348 University Institutional Review Board reviewed the protocol for this study and deemed it to be
349 exempt under U.S. federal law.

350

351 **AUTHOR CONTRIBUTIONS**

352 NKS is the sole author, had full access to the data, and takes responsibility for the
353 integrity of the data and the accuracy of the data analysis, and the entirety of the
354 manuscript. NKS contributions include conceptualization, design of the study, statistical
355 analysis, interpreting the data, and writing and revising the manuscript.

356

357 **FUNDING**

358 This project was supported in part by NIH/NCATS CTSA KL2TR002547. Its contents
359 are solely the responsibility of the author and do not necessarily represent the official
360 views of the NIH.

361

362 **CONFLICTS OF INTEREST**

363 The author of this report has no conflicts of interest to disclose.

364

365 **ACKNOWLEDGEMENTS**

366 The author would like to thank Obada Farhan, MS (Case Western Reserve University)
367 and R. Henry Olaisen for their roles in writing some of the R code used in the analysis,
368 and Kurt Stange, MD, PhD for his mentorship on the career development award that
369 supported this work.

370

371

372 REFERENCES

- 373 1. Buttorff C, Ruder T, Bauman M. *Multiple Chronic Conditions in the United States*. RAND
374 Corporation; 2017. Accessed October 5, 2019. <https://www.rand.org/pubs/tools/TL221.html>
- 375 2. Fortin M, Bravo G, Hudon C, et al. Relationship between multimorbidity and health-related
376 quality of life of patients in primary care. *Qual Life Res Int J Qual Life Asp Treat Care*
377 *Rehabil.* 2006;15(1):83-91. doi:10.1007/s11136-005-8661-z
- 378 3. Gijzen R, Hoeymans N, Schellevis FG, Ruwaard D, Satariano WA, van den Bos GA.
379 Causes and consequences of comorbidity: a review. *J Clin Epidemiol.* 2001;54(7):661-674.
380 doi:10.1016/s0895-4356(00)00363-2
- 381 4. Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple
382 chronic conditions in the elderly. *Arch Intern Med.* 2002;162(20):2269-2276.
383 doi:10.1001/archinte.162.20.2269
- 384 5. Koroukian SM, Schiltz N, Warner DF, et al. Combinations of Chronic Conditions,
385 Functional Limitations, and Geriatric Syndromes that Predict Health Outcomes. *J Gen*
386 *Intern Med.* 2016;31(6):630-637. doi:10.1007/s11606-016-3590-9
- 387 6. Schiltz NK, Warner DF, Sun J, et al. Identifying Specific Combinations of Multimorbidity
388 that Contribute to Health Care Resource Utilization: An Analytic Approach. *Med Care.*
389 2017;55(3):276-284. doi:10.1097/MLR.0000000000000660
- 390 7. Buffel du Vaure C, Ravaud P, Baron G, Barnes C, Gilberg S, Boutron I. Potential workload
391 in applying clinical practice guidelines for patients with chronic conditions and
392 multimorbidity: a systematic analysis. *BMJ Open.* 2016;6(3):e010119.
393 doi:10.1136/bmjopen-2015-010119
- 394 8. Tinetti ME, Bogardus ST, Agostini JV. Potential pitfalls of disease-specific guidelines for
395 patients with multiple conditions. *N Engl J Med.* 2004;351(27):2870-2874.
396 doi:10.1056/NEJMsb042458
- 397 9. Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical Practice Guidelines and
398 Quality of Care for Older Patients With Multiple Comorbid Diseases: Implications for Pay
399 for Performance. *JAMA.* 2005;294(6):716-724. doi:10.1001/jama.294.6.716
- 400 10. Boyd CM, Kent DM. Evidence-Based Medicine and the Hard Problem of Multimorbidity. *J*
401 *Gen Intern Med.* 2014;29(4):552-553. doi:10.1007/s11606-013-2658-z
- 402 11. Furman D, Campisi J, Verdin E, et al. Chronic inflammation in the etiology of disease
403 across the life span. *Nat Med.* 2019;25(12):1822-1832. doi:10.1038/s41591-019-0675-0
- 404 12. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and
405 other disorders. *Nat Rev Neurosci.* 2011;12(12):723-738. doi:10.1038/nrn3114
- 406 13. James SL, Abate D, Abate KH, et al. Global, regional, and national incidence, prevalence,
407 and years lived with disability for 354 diseases and injuries for 195 countries and
408 territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017.
409 *The Lancet.* 2018;392(10159):1789-1858. doi:10.1016/S0140-6736(18)32279-7

- 410 14. Fortin M, Stewart M, Poitras ME, Almirall J, Maddocks H. A Systematic Review of
411 Prevalence Studies on Multimorbidity: Toward a More Uniform Methodology. *Ann Fam*
412 *Med.* 2012;10(2):142-151. doi:10.1370/afm.1337
- 413 15. Salive ME. Multimorbidity in Older Adults. *Epidemiol Rev.* 2013;35(1):75-83.
414 doi:10.1093/epirev/mxs009
- 415 16. Vogeli C, Shields AE, Lee TA, et al. Multiple chronic conditions: prevalence, health
416 consequences, and implications for quality, care management, and costs. *J Gen Intern*
417 *Med.* 2007;22 Suppl 3:391-395. doi:10.1007/s11606-007-0322-1
- 418 17. Quiñones AR, Markwardt S, Botoseneanu A. Multimorbidity Combinations and Disability in
419 Older Adults. *J Gerontol A Biol Sci Med Sci.* 2016;71(6):823-830.
420 doi:10.1093/gerona/glw035
- 421 18. Quiñones AR, Markwardt S, Thielke S, Rostant O, Vásquez E, Botoseneanu A.
422 Prospective Disability in Different Combinations of Somatic and Mental Multimorbidity. *J*
423 *Gerontol Ser A.* 2018;73(2):204-210. doi:10.1093/gerona/glx100
- 424 19. Valderas JM, Gangannagaripalli J, Nolte E, et al. Quality of care assessment for people
425 with multimorbidity. *J Intern Med.* 2019;285(3):289-300. doi:10.1111/joim.12881
- 426 20. Lochner KA, Cox CS. Prevalence of multiple chronic conditions among Medicare
427 beneficiaries, United States, 2010. *Prev Chronic Dis.* 2013;10:E61.
428 doi:10.5888/pcd10.120137
- 429 21. Steinman MA, Lee SJ, Boscardin WJ, et al. Patterns of Multimorbidity in Elderly Veterans.
430 *J Am Geriatr Soc.* 2012;60(10):1872-1880. doi:10.1111/j.1532-5415.2012.04158.x
- 431 22. Garin N, Koyanagi A, Chatterji S, et al. Global Multimorbidity Patterns: A Cross-Sectional,
432 Population-Based, Multi-Country Study. *J Gerontol A Biol Sci Med Sci.* 2016;71(2):205-
433 214. doi:10.1093/gerona/glv128
- 434 23. Ward BW. Prevalence of Multiple Chronic Conditions Among US Adults: Estimates From
435 the National Health Interview Survey, 2010. *Prev Chronic Dis.* 2013;10.
436 doi:10.5888/pcd10.120203
- 437 24. Weiss CO, Boyd CM, Yu Q, Wolff JL, Leff B. Patterns of Prevalent Major Chronic Disease
438 Among Older Adults in the United States. *JAMA.* 2007;298(10):1158-1162.
439 doi:10.1001/jama.298.10.1160-b
- 440 25. Rocca WA, Boyd CM, Grossardt BR, et al. Prevalence of Multimorbidity in a
441 Geographically Defined American Population: Patterns by Age, Sex, and Race/Ethnicity.
442 *Mayo Clin Proc.* 2014;89(10):1336-1349. doi:10.1016/j.mayocp.2014.07.010
- 443 26. Koroukian SM, Schiltz NK, Warner DF, et al. Multimorbidity: constellations of conditions
444 across subgroups of midlife and older individuals, and related Medicare expenditures. *J*
445 *Comorbidity.* 2017;7(1):33-43. doi:10.15256/joc.2017.7.91

- 446 27. Cohen J. *Methodology Report #1: Design and Methods of the Medical Expenditure Panel*
447 *Survey Household Component*. Agency for Health Care Policy and Research; 1997.
448 Accessed October 26, 2014. http://meps.ahrq.gov/data_files/publications/mr1/mr1.shtml
- 449 28. Agency for Healthcare Research and Quality. MEPS HC036: 1996-2015 Pooled
450 Estimation File. Accessed May 25, 2022.
451 https://meps.ahrq.gov/data_stats/download_data/pufs/h36/h36u15doc.shtml
- 452 29. Sommers J. *An Examination of State Estimates Using Multiple Years of Data from the*
453 *Medical Expenditure Panel Survey, Household Component*. Agency for Healthcare
454 Research & Quality; 2006. Accessed October 6, 2022.
455 <https://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.568.2822&rep=rep1&type=pdf>
- 456 30. Machlin S, Cohen J, Elixhauser A, Beauregard K, Steiner C. Sensitivity of Household
457 Reported Medical Conditions in the Medical Expenditure Panel Survey: *Med Care*.
458 2009;47(6):618-625. doi:10.1097/MLR.0b013e318195fa79
- 459 31. Fortin M, Almirall J, Nicholson K. Development of a Research Tool to Document Self-
460 Reported Chronic Conditions in Primary Care. *J Comorbidity*. 2017;7(1):117-123.
461 doi:10.15256/joc.2017.7.122
- 462 32. Nicholson K, Bauer M, Terry AL, Fortin M, Williamson T, Thind A. The multimorbidity
463 cluster analysis tool: identifying combinations and permutations of multiple chronic
464 diseases using a record-level computational analysis. *BMJ Health Care Inform*.
465 2017;24(4):339-343. doi:10.14236/jhi.v24i4.962
- 466 33. Nicholson K, Terry AL, Fortin M, Williamson T, Bauer M, Thind A. Prevalence,
467 characteristics, and patterns of patients with multimorbidity in primary care: a retrospective
468 cohort analysis in Canada. *Br J Gen Pract*. 2019;69(686):e647-e656.
469 doi:10.3399/bjgp19X704657
- 470 34. Machlin, S, Dougherty D. Overview of Methodology for Imputing Missing Expenditure Data
471 in the Medical Expenditure Panel Survey. Published online March 2007.
472 http://www.meps.ahrq.gov/mepsweb/data_files/publications/mr19/mr19.pdf
- 473 35. Dunn A, Grosse SD, Zuvekas SH. Adjusting Health Expenditures for Inflation: A Review of
474 Measures for Health Services Research in the United States. *Health Serv Res*.
475 2018;53(1):175-196. doi:10.1111/1475-6773.12612
- 476 36. Agrawal R, Srikant R. Fast algorithms for mining association rules. In: *Proc. of 20th Intl.*
477 *Conf. on VLDB*. ; 1994:487-499.
- 478 37. Lumley T. *Complex Surveys: A Guide to Analysis Using R*. Wiley; 2010.
- 479 38. Ho VP, Schiltz NK, Reimer AP, Madigan EA, Koroukian SM. High-Risk Comorbidity
480 Combinations in Older Patients Undergoing Emergency General Surgery: COMORBIDITY
481 COMBINATIONS IN EMERGENCY SURGERY. *J Am Geriatr Soc*. 2019;67(3):503-510.
482 doi:10.1111/jgs.15682

- 483 39. Bayardo RJ, Agrawal R, Gunopulos D. Constraint-based rule mining in large, dense
484 databases. In: *Proceedings 15th International Conference on Data Engineering (Cat.*
485 *No.99CB36337)*. IEEE; 1999:188-197. doi:10.1109/ICDE.1999.754924
- 486 40. Hahsler M, Buchta C, Gruen B, Hornik K, Borgelt C. arules: Mining Association Rules and
487 Frequent Itemsets. Published online October 2, 2016. Accessed January 31, 2017.
488 <https://cran.r-project.org/web/packages/arules/index.html>
- 489 41. Lumley T. Analysis of complex survey samples. *J Stat Softw.* 2004;9(1):1-19.
- 490 42. Lithell H. Hypertension and Hyperlipidemia: A Review. *Am J Hypertens.*
491 1993;6(11_Pt_2):303S-308S. doi:10.1093/ajh/6.11.303S
- 492 43. Muth C, Blom JW, Smith SM, et al. Evidence supporting the best clinical management of
493 patients with multimorbidity and polypharmacy: a systematic guideline review and expert
494 consensus. *J Intern Med.* 2019;285(3):272-288. doi:10.1111/joim.12842
- 495 44. Fortin M, Bravo G, Hudon C, Vanasse A, Lapointe L. Prevalence of multimorbidity among
496 adults seen in family practice. *Ann Fam Med.* 2005;3(3):223-228. doi:10.1370/afm.272
- 497 45. Mokraoui NM, Haggerty J, Almirall J, Fortin M. Prevalence of self-reported multimorbidity in
498 the general population and in primary care practices: a cross-sectional study. *BMC Res*
499 *Notes.* 2016;9:314. doi:10.1186/s13104-016-2121-4
- 500 46. Smith SM, Wallace E, O'Dowd T, Fortin M. Interventions for improving outcomes in
501 patients with multimorbidity in primary care and community settings. *Cochrane Database*
502 *Syst Rev.* 2021;1:CD006560. doi:10.1002/14651858.CD006560.pub4
- 503 47. Zeiss AM, Steffen AM. Interdisciplinary health care teams: The basic unit of geriatric care.
504 In: *The Practical Handbook of Clinical Gerontology*. Sage Publications, Inc; 1996:423-450.
- 505 48. Mate KS, Berman A, Laderman M, Kabcenell A, Fulmer T. Creating Age-Friendly Health
506 Systems – A vision for better care of older adults. *Healthcare.* 2018;6(1):4-6.
507 doi:10.1016/j.hjdsi.2017.05.005
- 508 49. O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. STOPP/START
509 criteria for potentially inappropriate prescribing in older people: version 2. *Age Ageing.*
510 2015;44(2):213-218. doi:10.1093/ageing/afu145
- 511 50. 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American
512 Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate
513 Medication Use in Older Adults. *J Am Geriatr Soc.* 2019;67(4):674-694.
514 doi:10.1111/jgs.15767
- 515 51. Boersma P, Black LI, Ward BW. Prevalence of Multiple Chronic Conditions Among US
516 Adults, 2018. *Prev Chronic Dis.* 2020;17:E106. doi:10.5888/pcd17.200130
- 517 52. Quiñones AR, Botosaneanu A, Markwardt S, et al. Racial/ethnic differences in
518 multimorbidity development and chronic disease accumulation for middle-aged adults.
519 *PLoS One.* 2019;14(6):e0218462. doi:10.1371/journal.pone.0218462

- 520 53. Quiñones AR, Valenzuela SH, Huguet N, et al. Prevalent Multimorbidity Combinations
521 Among Middle-Aged and Older Adults Seen in Community Health Centers. *J Gen Intern*
522 *Med*. Published online January 28, 2022. doi:10.1007/s11606-021-07198-2
- 523 54. Lee Y, Kim H, Jeong H, Noh Y. Patterns of Multimorbidity in Adults: An Association Rules
524 Analysis Using the Korea Health Panel. *Int J Environ Res Public Health*. 2020;17(8):2618.
525 doi:10.3390/ijerph17082618
- 526 55. Zemedikun DT, Gray LJ, Khunti K, Davies MJ, Dhalwani NN. Patterns of Multimorbidity in
527 Middle-Aged and Older Adults: An Analysis of the UK Biobank Data. *Mayo Clin Proc*.
528 2018;93(7):857-866. doi:10.1016/j.mayocp.2018.02.012
- 529 56. Britt HC, Harrison CM, Miller GC, Knox SA. Prevalence and patterns of multimorbidity in
530 Australia. *Med J Aust*. 2008;189(2):72-77. doi:10.5694/j.1326-5377.2008.tb01919.x
- 531 57. Schiltz NK, Chagin K, Sehgal AR. Clustering of Social Determinants of Health Among
532 Patients. *J Prim Care Community Health*. 2022;13:21501319221113544.
533 doi:10.1177/21501319221113543
- 534 58. Harpaz R, DuMouchel W, Shah NH, Madigan D, Ryan P, Friedman C. Novel Data Mining
535 Methodologies for Adverse Drug Event Discovery and Analysis. *Clin Pharmacol Ther*.
536 2012;91(6):1010-1021. doi:10.1038/clpt.2012.50
- 537 59. Bernard D, Cowan C, Selden T, Cai L, Catlin A, Heffler S. Reconciling medical expenditure
538 estimates from the MEPS and NHEA, 2007. *Medicare Medicaid Res Rev*.
539 2012;2(4):mmrr.002.04.a09. doi:10.5600/mmrr.002.04.a09
- 540 60. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with
541 administrative data. *Med Care*. 1998;36(1):8-27.
- 542 61. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-
543 CM administrative databases. *J Clin Epidemiol*. 1992;45(6):613-619. doi:10.1016/0895-
544 4356(92)90133-8
- 545 62. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic
546 comorbidity in longitudinal studies: Development and validation. *J Chronic Dis*.
547 1987;40(5):373-383. doi:10.1016/0021-9681(87)90171-8
- 548 63. Elixhauser A, Steiner C, Palmer L. *Clinical Classification Software (CCS), 2012*. U.S.
549 Agency for Healthcare Research & Quality.; 2012. [http://www.hcup-](http://www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp)
550 [us.ahrq.gov/toolssoftware/ccs/ccs.jsp](http://www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp)
- 551 64. Wei WQ, Bastarache LA, Carroll RJ, et al. Evaluating phecodes, clinical classification
552 software, and ICD-9-CM codes for phenome-wide association studies in the electronic
553 health record. *PLOS ONE*. 2017;12(7):e0175508. doi:10.1371/journal.pone.0175508
- 554 65. Stirland LE, González-Saavedra L, Mullin DS, Ritchie CW, Muniz-Terrera G, Russ TC.
555 Measuring multimorbidity beyond counting diseases: systematic review of community and
556 population studies and guide to index choice. *BMJ*. 2020;368:m160. doi:10.1136/bmj.m160

- 557 66. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities,
558 and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City
559 Area. *JAMA*. 2020;323(20):2052-2059. doi:10.1001/jama.2020.6775
- 560 67. Emami A, Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of Underlying Diseases in
561 Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis. *Arch Acad*
562 *Emerg Med*. 2020;8(1):e35.
- 563 68. Chudasama YV, Zaccardi F, Gillies CL, et al. Patterns of multimorbidity and risk of severe
564 SARS-CoV-2 infection: an observational study in the U.K. *BMC Infect Dis*. 2021;21(1):908.
565 doi:10.1186/s12879-021-06600-y
- 566 69. Hernandez-Romieu AC, Carton TW, Saydah S, et al. Prevalence of Select New Symptoms
567 and Conditions Among Persons Aged Younger Than 20 Years and 20 Years or Older at 31
568 to 150 Days After Testing Positive or Negative for SARS-CoV-2. *JAMA Netw Open*.
569 2022;5(2):e2147053. doi:10.1001/jamanetworkopen.2021.47053
- 570 70. Wanga V. Long-Term Symptoms Among Adults Tested for SARS-CoV-2 — United States,
571 January 2020–April 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70.
572 doi:10.15585/mmwr.mm7036a1
- 573 71. Xie Y, Al-Aly Z. Risks and burdens of incident diabetes in long COVID: a cohort study.
574 *Lancet Diabetes Endocrinol*. 2022;10(5):311-321. doi:10.1016/S2213-8587(22)00044-4
- 575 72. Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. *Nat Med*.
576 2022;28(3):583-590. doi:10.1038/s41591-022-01689-3
- 577 73. Shanley JE, Valenciano AF, Timmons G, et al. Longitudinal evaluation of neurologic-post
578 acute sequelae SARS-CoV-2 infection symptoms. *Ann Clin Transl Neurol*. 2022;9(7):995-
579 1010. doi:10.1002/acn3.51578
- 580

581 **FIGURE CAPTIONS**

582

583 **Figure 1: Highly prevalent specific combinations of multimorbidity and associated cost and**
584 **perceived poor health.** The figure shows combinations of conditions with an estimated prevalence of 5
585 million or more adults in the United States. Data source: the 2016-2019 Medical Expenditure Panel
586 Survey (MEPS). Weighted estimates and 95% confidence intervals were calculated by applying
587 population weights using Taylor-series methods (i.e. complex survey methods) to account for the complex
588 sampling design of the MEPS. Weighted estimates have been annualized by taking the average over the
589 four-year study period. X-axes for prevalence and cost are on the logarithmic scale. Results are sorted by
590 prevalence. Cost is measured as total annual medical expenditures in 2019 US Dollars, and perceived
591 health is an answer of “fair” or “poor” on a 5-point question asking respondents to rank their overall
592 health.

593

594 **Figure 2: Specific combinations of multimorbidity ranked highest in terms of average cost or**
595 **perceived poor health.** The figure shows the specific combinations of multimorbidity that ranked in the
596 top 20 in terms of highest average cost per person or top 20 highest percentage with self-reported poor
597 health. A total of 28 conditions met either criterion, with 12 meeting both. Data source: 2016-2019 Medical
598 Expenditure Panel Survey (MEPS). Weighted estimates and 95% confidence intervals were calculated by
599 applying population weights using Taylor-series methods (i.e. complex survey methods) to account for the
600 complex sampling design of the MEPS. Weighted estimates have been annualized by taking the average
601 over the four-year study period. Adjusted odds ratios were calculated using log-binomial models adjusting
602 for age, race, and sex, and Taylor-series methods for standard errors. X-axes are on the logarithmic
603 scale, and results are sorted by prevalence.

604

605 **Figure 3: Top ten most prevalent specific combinations of multimorbidity by sex and associated**
606 **cost and perceived poor health.** The figure shows the top ten combinations of conditions as ranked by
607 prevalence by sex among adults in the United States. Panel A shows data on males, and Panel B shows
608 data on females. Data source: the 2016-2019 Medical Expenditure Panel Survey (MEPS). Weighted
609 estimates and 95% confidence intervals were calculated by applying population weights using Taylor-
610 series methods (i.e. complex survey methods) to account for the complex sampling design of the MEPS.
611 Weighted estimates have been annualized by taking the average over the four-year study period. X-axes
612 for prevalence and cost are on the logarithmic scale. Results are sorted by prevalence. Cost is measured
613 as total annual medical expenditures in 2019 US Dollars, and perceived health is an answer of “fair” or
614 “poor” on a 5-point question asking respondents to rank their overall health.



615

616

Table 1: Number of Chronic Conditions Treated among U.S. Adults by Population Characteristics

Table 1 caption: Survey-weighted estimates from pooling the 2016-2019 Medical Expenditure Panel Survey. Weighted estimates have been annualized by taking the average over the four year study period. Row percentages are reported under each count of conditions column. Medical expenditures are reported in 2019 US Dollars (USD).

Variable	No. in unweighted sample	Weighted No. of Adults	0 chronic conditions, Row %	1+ chronic conditions, Row %	2+ chronic conditions, Row %	3+ chronic conditions, Row %	4+ chronic conditions, Row %
Total	89,947	249,221,000	47.4%	52.6%	32.9%	20.7%	12.3%
Age Group							
18 - 39	17,745	94,573,000	73.9%	26.1%	7.9%	2.7%	0.9%
40 - 64	19,776	102,614,000	41.1%	58.9%	35.5%	20.0%	10.6%
65 and older	9,311	52,034,000	11.6%	88.4%	73.0%	54.9%	36.1%
Sex							
Male	21,671	120,330,000	52.4%	47.6%	29.9%	18.8%	10.7%
Female	25,161	128,891,000	42.7%	57.3%	35.7%	22.5%	13.7%
Race / Ethnicity							
Hispanic	12,841	40,533,000	63.3%	36.7%	19.5%	11.6%	6.2%
Non-Hispanic White only	21,164	156,551,000	40.7%	59.3%	38.4%	24.5%	14.9%
Non-Hispanic Black only	8,113	29,523,000	53.0%	47.0%	28.9%	18.0%	10.1%
Non-Hispanic Asian only	3,355	15,133,000	62.4%	37.6%	20.0%	11.3%	5.4%
Other or Multiple Race	1,359	7,481,000	47.8%	52.2%	32.7%	21.0%	12.8%
Self-rated Poor Health	7,201	31,085,000	19.0%	81.0%	64.6%	48.8%	34.3%
Per capita medical expenditures in 2019 USD (Median, IQR)	---	---	\$322 (\$0 – \$1,382)	\$4,176 (\$1,523 – \$11,067)	\$6,208 (\$2,558 – \$14,858)	\$8,177 (\$3,610 – \$18,756)	\$10,821 (\$5,045 – \$23,712)
Per capita out-of-pocket medical expenditures in 2019 USD (Median, IQR)			\$30 (\$0 – \$287)	\$542 (\$167 – \$1,401)	\$695 (\$243 – \$1,681)	\$808 (\$292 – \$1,865)	\$903 (\$333 – \$2,080)









Figure 3

Panel A: Males



Panel B: Females

